Astrazeneca Plc ADR (AZN)

$71.13 -0.68 (-0.95%)
Market Cap 222.71B
Revenue (ttm) 54.07B
Net Income (ttm) 7.04B
EPS (ttm) N/A
PE Ratio 16.39
Forward PE 15.80
Profit Margin 13.01%
Debt to Equity Ratio 0.73
Volume 2,729,800
Avg Vol 4,434,386
Day's Range N/A - N/A
Shares Out 3.10B
Stochastic %K 60%
Beta 0.37
Analysts Strong Sell
Price Target $85.09

Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modi...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 44 20 3749 5000
Fax: 44 1223 352 858
Address:
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom
RobotMumba100
RobotMumba100 Jul. 10 at 4:12 PM
$TEM this is Tempus... 300+ petabytes of data this in particular is the reason why I'm all in... $AZN $PFE $BNTX
0 · Reply
Chipwars
Chipwars Jul. 10 at 11:53 AM
$AZN https://www.tipranks.com/news/the-fly/astrazeneca-price-target-raised-to-97-from-93-at-berenberg-thefly
0 · Reply
Chipwars
Chipwars Jul. 10 at 11:39 AM
$AZN In addition to Berenberg Bank, AstraZeneca also received a Buy from UBS’s Matthew Weston in a report issued on July 7
1 · Reply
Chipwars
Chipwars Jul. 10 at 11:38 AM
$AZN In a report released yesterday, Luisa Hector from Berenberg Bank maintained a Buy rating on AstraZeneca, with a price target of £142.00. https://www.theglobeandmail.com/investing/markets/stocks/AZN/pressreleases/33314908/astrazeneca-azn-receives-a-buy-from-berenberg-bank/
0 · Reply
Chipwars
Chipwars Jul. 10 at 11:35 AM
$AZN https://pmlive.com/pharma_news/astrazenecas-imfinzi-regimen-approved-by-ec-to-treat-muscle-invasive-bladder-cancer/
0 · Reply
Chipwars
Chipwars Jul. 10 at 11:34 AM
$AZN Astrazeneca is such a cheap, safe stock at the moment. https://www.proactiveinvestors.com/companies/news/1074407/astrazeneca-market-isn-t-pricing-in-the-potential-of-late-stage-pipeline-says-bank-1074407.html
0 · Reply
Drugtrade
Drugtrade Jul. 10 at 12:38 AM
$MRK $AZN $LLY top 3 non US holdings on my long port so far .. lily is a bit high p/e so i dont have any atm
1 · Reply
pianoman439
pianoman439 Jul. 9 at 11:59 PM
$AZN can someone tell me about the new cancer drug launch in the US and Canada? I’m hearing this could be a GameChanger!
0 · Reply
GreenEnergy2022
GreenEnergy2022 Jul. 9 at 6:07 PM
$ALT First Product Candidate to Demonstrate Significant MASH Effects and Weight Loss at 24 Weeks $GILD $PFE $AZN $AMGN
0 · Reply
11thestate
11thestate Jul. 8 at 10:40 PM
🚨 Trump has proposed a 200% tariff on pharmaceuticals. Just saying: Pharma’s already one of the most sued sectors by investors. We’ve tracked 57 cases in just two years. $JNJ $PFE $MRK $LLY $AZN ➡️ 11th.com
0 · Reply
Latest News on AZN
AstraZeneca: Just What The Doctor Ordered

Jul 8, 2025, 7:00 AM EDT - 3 days ago

AstraZeneca: Just What The Doctor Ordered

Summit Therapeutics: AstraZeneca Partnership Could Be A Game-Changer, But Clinical Risks Remain

Jul 4, 2025, 5:10 AM EDT - 7 days ago

Summit Therapeutics: AstraZeneca Partnership Could Be A Game-Changer, But Clinical Risks Remain

SMMT

Report: Summit in talks for $15 billion partnership with AstraZeneca

Jul 3, 2025, 11:38 AM EDT - 8 days ago

Report: Summit in talks for $15 billion partnership with AstraZeneca

Summit considers up to $15 billion partnership with AstraZeneca, Bloomberg News reports

Jul 3, 2025, 10:39 AM EDT - 8 days ago

Summit considers up to $15 billion partnership with AstraZeneca, Bloomberg News reports

AstraZeneca exit: here's what it really means for the UK

Jul 2, 2025, 10:47 AM EDT - 9 days ago

AstraZeneca exit: here's what it really means for the UK

AstraZeneca boss ‘wants to shift stock market listing to US'

Jul 1, 2025, 1:30 PM EDT - 10 days ago

AstraZeneca boss ‘wants to shift stock market listing to US'

AstraZeneca CEO eyes US market listing, The Times reports

Jul 1, 2025, 10:59 AM EDT - 10 days ago

AstraZeneca CEO eyes US market listing, The Times reports

AstraZeneca: Navigating Challenges Across Geographies Well

Jul 1, 2025, 9:37 AM EDT - 10 days ago

AstraZeneca: Navigating Challenges Across Geographies Well

Onco-Innovations Welcomes AstraZeneca's Interest in Founding Role in PROmAI - an Inka-led AI-Oncology Consortium

Jun 27, 2025, 6:00 PM EDT - 14 days ago

Onco-Innovations Welcomes AstraZeneca's Interest in Founding Role in PROmAI - an Inka-led AI-Oncology Consortium

AstraZeneca's Datroway Approved to Treat Non-Small Cell Lung Cancer in U.S.

Jun 24, 2025, 2:32 AM EDT - 18 days ago

AstraZeneca's Datroway Approved to Treat Non-Small Cell Lung Cancer in U.S.

US approves AstraZeneca, Daiichi's treatment for lung cancer

Jun 24, 2025, 2:15 AM EDT - 18 days ago

US approves AstraZeneca, Daiichi's treatment for lung cancer

5 Ideal 'Safer' Dividend Buys From Bloomberg's June Watch List

Jun 14, 2025, 3:26 AM EDT - 4 weeks ago

5 Ideal 'Safer' Dividend Buys From Bloomberg's June Watch List

AVGO CL EMR ESS FOX HSBC KLAC

AstraZeneca Teams Up With CSPC Pharmaceuticals With Deal Valued at Up to $5.33 Billion

Jun 13, 2025, 5:29 AM EDT - 4 weeks ago

AstraZeneca Teams Up With CSPC Pharmaceuticals With Deal Valued at Up to $5.33 Billion

AstraZeneca agrees to research deal worth up to $5.22 billion with CSPC

Jun 13, 2025, 4:40 AM EDT - 4 weeks ago

AstraZeneca agrees to research deal worth up to $5.22 billion with CSPC

AstraZeneca CEO: We totally agree with President Trump on this

Jun 4, 2025, 5:30 PM EDT - 5 weeks ago

AstraZeneca CEO: We totally agree with President Trump on this

Healthy Returns: AstraZeneca, Pfizer, Gilead and other drugmakers release promising cancer drug data at ASCO

Jun 3, 2025, 3:34 PM EDT - 5 weeks ago

Healthy Returns: AstraZeneca, Pfizer, Gilead and other drugmakers release promising cancer drug data at ASCO

GILD PFE AMGN BMY BNTX MRK

AstraZeneca CEO Pascal Soriot on breast cancer drug trial

Jun 2, 2025, 11:06 AM EDT - 5 weeks ago

AstraZeneca CEO Pascal Soriot on breast cancer drug trial

AstraZeneca CEO on breast cancer drug trial: This is the future of cancer treatment

Jun 2, 2025, 8:41 AM EDT - 5 weeks ago

AstraZeneca CEO on breast cancer drug trial: This is the future of cancer treatment

Experimental AstraZeneca pill helps cut risk of breast cancer progression

Jun 2, 2025, 7:14 AM EDT - 5 weeks ago

Experimental AstraZeneca pill helps cut risk of breast cancer progression

'Transformational' new drug could stop breast cancer tumours before they grow, trial finds

Jun 1, 2025, 8:43 AM EDT - 5 weeks ago

'Transformational' new drug could stop breast cancer tumours before they grow, trial finds

Blood test-guided treatment with AstraZeneca pill cut risk of breast cancer progression, study finds

Jun 1, 2025, 8:04 AM EDT - 5 weeks ago

Blood test-guided treatment with AstraZeneca pill cut risk of breast cancer progression, study finds

Camizestrant reduced the risk of disease progression or death by 56% in patients with advanced HR-positive breast cancer with an emergent ESR1 tumor mutation in SERENA-6 Phase III trial

Jun 1, 2025, 8:00 AM EDT - 5 weeks ago

Camizestrant reduced the risk of disease progression or death by 56% in patients with advanced HR-positive breast cancer with an emergent ESR1 tumor mutation in SERENA-6 Phase III trial

Danaher Announces Diagnostic Development and Commercialization Partnership to Scale Precision Medicine

May 29, 2025, 4:30 PM EDT - 6 weeks ago

Danaher Announces Diagnostic Development and Commercialization Partnership to Scale Precision Medicine

DHR

Why AstraZeneca May Be 2025's Most Underrated Pharma Stock

May 25, 2025, 4:50 AM EDT - 6 weeks ago

Why AstraZeneca May Be 2025's Most Underrated Pharma Stock

Aptar Digital Health Announces Licensing Agreement With AstraZeneca to Develop AI-Powered Screening Algorithms

May 22, 2025, 8:00 AM EDT - 7 weeks ago

Aptar Digital Health Announces Licensing Agreement With AstraZeneca to Develop AI-Powered Screening Algorithms

AstraZeneca's record seventh year of plenary data at ASCO furthers ambition to redefine breast cancer care and transform outcomes in gastric cancer

May 21, 2025, 7:00 AM EDT - 7 weeks ago

AstraZeneca's record seventh year of plenary data at ASCO furthers ambition to redefine breast cancer care and transform outcomes in gastric cancer

Statistically significant and clinically meaningful BATURA Phase III trial results provide new evidence for AIRSUPRA as standard of care for as-needed rescue treatment in asthma

May 19, 2025, 12:34 PM EDT - 7 weeks ago

Statistically significant and clinically meaningful BATURA Phase III trial results provide new evidence for AIRSUPRA as standard of care for as-needed rescue treatment in asthma

35 Barron's Pro-Picks: One Ideal May DiviDog

May 18, 2025, 4:51 AM EDT - 7 weeks ago

35 Barron's Pro-Picks: One Ideal May DiviDog

AGNC ASIX BDX CRM EPD FLMI FOX

BioInvent Announces Updated Phase 2a Triple Combination Arm Data of BI-1206, rituximab, and Calquence for the Treatment of Non-Hodgkin's Lymphoma

May 14, 2025, 9:40 AM EDT - 2 months ago

BioInvent Announces Updated Phase 2a Triple Combination Arm Data of BI-1206, rituximab, and Calquence for the Treatment of Non-Hodgkin's Lymphoma

AstraZeneca to showcase latest research on comprehensive portfolio and pipeline aimed at transforming respiratory diseases at ATS 2025

May 13, 2025, 7:00 AM EDT - 2 months ago

AstraZeneca to showcase latest research on comprehensive portfolio and pipeline aimed at transforming respiratory diseases at ATS 2025

Dr. Scott Gottlieb: What to expect from President Trump's executive order to lower drug prices

May 12, 2025, 12:36 PM EDT - 2 months ago

Dr. Scott Gottlieb: What to expect from President Trump's executive order to lower drug prices

ABBV AMGN GILD GSK JNJ LLY MRK

Global Pharma Stocks Fall as Trump Plans to Cut Drug Prices

May 12, 2025, 5:30 AM EDT - 2 months ago

Global Pharma Stocks Fall as Trump Plans to Cut Drug Prices

ABBV AMGN GSK JNJ LLY MRK NVO

Pharmaceutical stocks slide as Trump vows to cut US prescription drug prices ‘by 30-80%'

May 12, 2025, 3:37 AM EDT - 2 months ago

Pharmaceutical stocks slide as Trump vows to cut US prescription drug prices ‘by 30-80%'

GSK NVO

IMFINZI® (durvalumab) regimen demonstrated statistically significant and clinically meaningful improvement in disease-free survival for high-risk non-muscle-invasive bladder cancer in POTOMAC Phase III trial

May 9, 2025, 7:00 AM EDT - 2 months ago

IMFINZI® (durvalumab) regimen demonstrated statistically significant and clinically meaningful improvement in disease-free survival for high-risk non-muscle-invasive bladder cancer in POTOMAC Phase III trial

AstraZeneca's Breztri meets main goals of late-stage asthma trials

May 2, 2025, 2:20 AM EDT - 2 months ago

AstraZeneca's Breztri meets main goals of late-stage asthma trials

AstraZeneca has built resilient supply chains in U.S., China: CEO

Apr 29, 2025, 12:08 PM EDT - 2 months ago

AstraZeneca has built resilient supply chains in U.S., China: CEO

Pharma firms maastraz

Apr 29, 2025, 12:06 PM EDT - 2 months ago

Pharma firms maastraz

GSK NVO NVS

AstraZeneca PLC (AZN) Q1 2025 Earnings Conference Call Transcript

Apr 29, 2025, 11:46 AM EDT - 2 months ago

AstraZeneca PLC (AZN) Q1 2025 Earnings Conference Call Transcript

AstraZeneca CEO talks tariffs, first quarter earnings

Apr 29, 2025, 11:35 AM EDT - 2 months ago

AstraZeneca CEO talks tariffs, first quarter earnings

AstraZeneca Q1 Earnings Rise, But China Drug Allegations May Lead To $8 Million Penalty

Apr 29, 2025, 10:18 AM EDT - 2 months ago

AstraZeneca Q1 Earnings Rise, But China Drug Allegations May Lead To $8 Million Penalty

AstraZeneca to keep 2025 forecast if US pharmaceutical tariffs in line with other sectors

Apr 29, 2025, 5:16 AM EDT - 2 months ago

AstraZeneca to keep 2025 forecast if US pharmaceutical tariffs in line with other sectors

AstraZeneca Sales, Earnings Rise; Warns of Mounting Legal Challenges in China

Apr 29, 2025, 4:10 AM EDT - 2 months ago

AstraZeneca Sales, Earnings Rise; Warns of Mounting Legal Challenges in China

AstraZeneca says may face further import tax fine from China

Apr 29, 2025, 2:10 AM EDT - 2 months ago

AstraZeneca says may face further import tax fine from China

AstraZeneca's Q1 2025 Financial Results

Apr 29, 2025, 2:00 AM EDT - 2 months ago

AstraZeneca's Q1 2025 Financial Results

SOPHiA GENETICS Announces Expanded Collaboration with AstraZeneca to Accelerate Liquid Biopsy Testing Globally from AACR

Apr 28, 2025, 12:00 PM EDT - 2 months ago

SOPHiA GENETICS Announces Expanded Collaboration with AstraZeneca to Accelerate Liquid Biopsy Testing Globally from AACR

SOPH

Tempus Signs Expanded Strategic Agreements with AstraZeneca and Pathos to Develop the Largest Multimodal Foundation Model in Oncology

Apr 23, 2025, 8:00 AM EDT - 2 months ago

Tempus Signs Expanded Strategic Agreements with AstraZeneca and Pathos to Develop the Largest Multimodal Foundation Model in Oncology

TEM

AstraZeneca CEO says Europe must protect its health sovereignty, is falling behind on pharma investments

Apr 23, 2025, 7:28 AM EDT - 2 months ago

AstraZeneca CEO says Europe must protect its health sovereignty, is falling behind on pharma investments

AstraZeneca rejoins leading U.S. drug lobby group after two-year absence

Apr 22, 2025, 4:10 PM EDT - 2 months ago

AstraZeneca rejoins leading U.S. drug lobby group after two-year absence

LLY, NVO and AMGN Forecast – Pharma Stocks to Open Mixed

Apr 21, 2025, 9:00 AM EDT - 2 months ago

LLY, NVO and AMGN Forecast – Pharma Stocks to Open Mixed

ABBV AMGN BMY GSK JNJ LLY MRK

Selling America, Buying Europe - My Picks

Apr 20, 2025, 9:15 AM EDT - 2 months ago

Selling America, Buying Europe - My Picks

ASML NVO

RobotMumba100
RobotMumba100 Jul. 10 at 4:12 PM
$TEM this is Tempus... 300+ petabytes of data this in particular is the reason why I'm all in... $AZN $PFE $BNTX
0 · Reply
Chipwars
Chipwars Jul. 10 at 11:53 AM
$AZN https://www.tipranks.com/news/the-fly/astrazeneca-price-target-raised-to-97-from-93-at-berenberg-thefly
0 · Reply
Chipwars
Chipwars Jul. 10 at 11:39 AM
$AZN In addition to Berenberg Bank, AstraZeneca also received a Buy from UBS’s Matthew Weston in a report issued on July 7
1 · Reply
Chipwars
Chipwars Jul. 10 at 11:38 AM
$AZN In a report released yesterday, Luisa Hector from Berenberg Bank maintained a Buy rating on AstraZeneca, with a price target of £142.00. https://www.theglobeandmail.com/investing/markets/stocks/AZN/pressreleases/33314908/astrazeneca-azn-receives-a-buy-from-berenberg-bank/
0 · Reply
Chipwars
Chipwars Jul. 10 at 11:35 AM
$AZN https://pmlive.com/pharma_news/astrazenecas-imfinzi-regimen-approved-by-ec-to-treat-muscle-invasive-bladder-cancer/
0 · Reply
Chipwars
Chipwars Jul. 10 at 11:34 AM
$AZN Astrazeneca is such a cheap, safe stock at the moment. https://www.proactiveinvestors.com/companies/news/1074407/astrazeneca-market-isn-t-pricing-in-the-potential-of-late-stage-pipeline-says-bank-1074407.html
0 · Reply
Drugtrade
Drugtrade Jul. 10 at 12:38 AM
$MRK $AZN $LLY top 3 non US holdings on my long port so far .. lily is a bit high p/e so i dont have any atm
1 · Reply
pianoman439
pianoman439 Jul. 9 at 11:59 PM
$AZN can someone tell me about the new cancer drug launch in the US and Canada? I’m hearing this could be a GameChanger!
0 · Reply
GreenEnergy2022
GreenEnergy2022 Jul. 9 at 6:07 PM
$ALT First Product Candidate to Demonstrate Significant MASH Effects and Weight Loss at 24 Weeks $GILD $PFE $AZN $AMGN
0 · Reply
11thestate
11thestate Jul. 8 at 10:40 PM
🚨 Trump has proposed a 200% tariff on pharmaceuticals. Just saying: Pharma’s already one of the most sued sectors by investors. We’ve tracked 57 cases in just two years. $JNJ $PFE $MRK $LLY $AZN ➡️ 11th.com
0 · Reply
ZacksResearch
ZacksResearch Jul. 8 at 3:40 PM
$AZN’s cancer franchise is on fire — but can it keep the pace? Oncology sales jumped 13% in Q1 2025, fueled by blockbuster drugs and fresh approvals. Find out what could drive the next leg of growth 👉 https://www.zacks.com/stock/news/2567489/astrazeneca-boasts-strong-oncology-portfolio-can-it-sustain-growth?cid=sm-stocktwits-2-2567489-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2567489_TEASER
0 · Reply
ZacksResearch
ZacksResearch Jul. 8 at 2:24 PM
$AZN up 7.8% YTD — Can its oncology strength continue the momentum? 💊 🚀 Oncology sales surged 13% in Q1 2025, generating $5.6 billion, with strong performances from Tagrisso, Lynparza, Imfinzi, Calquence, and Enhertu. 🔬 New drug approvals and pipeline progress hint at sustained momentum despite industry challenges. Discover the full potential of AZN's oncology portfolio here 👉 https://www.zacks.com/stock/news/2567489/astrazeneca-boasts-strong-oncology-portfolio-can-it-sustain-growth?cid=sm-stocktwits-2-2567489-body-927&ADID=SYND_STOCKTWITS_TWEET_2_2567489_BODY_927
0 · Reply
Estimize
Estimize Jul. 8 at 12:03 PM
Wall St is expecting 1.09 EPS for $AZN Q2 [Reporting 07/29 BMO] http://www.estimize.com/intro/azn?chart=historical&metric_name=eps&utm_cont
0 · Reply
Quantumup
Quantumup Jul. 7 at 2:44 PM
Piper Sandler reiterated $VRNA Overweight-$160 and said " $VRNA's OHTUVAYRE COPD launch continues, further solidifying its trajectory to a blockbuster opportunity." $SNY - $REGN $AZN AMGN $GSK Piper Sandler went on to say:
0 · Reply
Power2k
Power2k Jul. 7 at 1:27 PM
$TIL $SMMT is worth 18b while we are at just 0.18B with a potential best-in-class PD-(L)1/VEGF bi-specific Ab? $AZN Why not buying Instil Bio straight out for 10-15B and call it a day? $BNTX
1 · Reply
GreenEnergy2022
GreenEnergy2022 Jul. 4 at 7:23 PM
$ALT This is impressive for a 24w trial $GILD $PFE $NVO $AZN
1 · Reply
twincam
twincam Jul. 4 at 3:50 PM
$AZN 🚨 AstraZeneca eyeing a move to the U.S. — chasing higher valuations, deeper pockets, and smoother FDA love. London sweating harder than a biotech in a CRL delay. $AZN 🧬📉➡️📈🇺🇸 https://www.theguardian.com/business/2025/jul/01/astrazeneca-boss-wants-to-shift-stock-market-listing-to-us
0 · Reply
DonCorleone77
DonCorleone77 Jul. 4 at 2:08 PM
$AZN AstraZeneca reports Imfinzi approved in EU for MIBC AstraZeneca's Imfinzi has been approved in the European Union for the treatment of adult patients with resectable muscle-invasive bladder cancer in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by Imfinzi as monotherapy adjuvant treatment after radicalcystectomy, the company announced.
0 · Reply
GreenEnergy2022
GreenEnergy2022 Jul. 4 at 11:14 AM
$ALT Last week, Altimmune showed best in class MASH resolution. Only GLP1 with stat sig on 24 w. Better data vs Survo, and that is in half of the time. Since Novo Nordisk got Priority Review from FDA, ALT will probably get the same/accelerated approval from FDA, and will be one of the first GLP1 wight MASH+ Weight loss to hit the market, and they will hit the market with best data, and much better Tolerability profile. $LLY $NVO $AZN $PFE
2 · Reply
East161stNY
East161stNY Jul. 3 at 10:36 PM
$AZN Buyout’s investments, all down hill
0 · Reply
Rage_Against_The_Machine
Rage_Against_The_Machine Jul. 3 at 9:36 PM
AstraZeneca ($AZN) flexes its R&D muscle with AZD0305 advancing in the red-hot GPRC5D therapy space. Multiple myeloma treatment demand is skyrocketing, and with their candidate in the pipeline alongside BMS and Sanofi, this could be oncology's next battleground. Their 39% R&D spend increase looks prescient now. https://www.prnewswire.com/news-releases/gprc5d-directed-therapies-market-is-anticipated-to-gain-momentum-during-the-forecast-period-20252034-owing-to-unmet-need-in-multiple-myeloma--delveinsight-302497458.html
0 · Reply
FractionalShareWhale
FractionalShareWhale Jul. 3 at 4:43 PM
$AZN buy and hold
0 · Reply